John is a senior executive with over 25 years experience at transforming technology-based companies into product-based organizations. He combines a unique set of strategic, financial, talent management, and operating skills to identify unmet medical needs optimizing an organization to translate cutting–edge technology into products that address our most pressing hard to treat diseases.
Prior to co-founding and joining Cour, John was Co-Founder and CEO of Tolera Therapeutics. He led the company from initial start up through manufacturing optimization, pre-clinical, completion of a phase 2 clinical trial and filing of a Phase 3 Special Protocol Assessment (SPA) with the FDA. The company built significant barriers to entry by achieving several orphan drug designations and issuance of composition of matter patents utilizing a unique patent strategy.
Prior to Tolera, he was President and CEO of Third Wave Technologies (NASDAQ: TWTI), a biotechnology company, where he led the transformation of a non-sustainable research tools business into a robust growth driven molecular diagnostics company primarily by leading the development of hard to detect infections and cancers. Third Wave was eventually sold for $600 million. John also served as a strategic consultant to DEKALB Genetics Corporation that was ultimately sold for $2.8 billion. John was with the Spencer Stuart and Egon Zehnder life sciences practice groups where he consulted with biotech and pharmaceutical firms. Receiving his BS – Accounting from Northern Illinois University in 1983, John started his career at Arthur Andersen and also worked for Price Waterhouse. He received his MBA from the Kellogg School of Management at Northwestern University.
Dr. Daniel Getts is an energetic executive focused on translating cutting edge scientific breakthroughs into meaningful medical therapies. Placing himself at the center of the academic/industry interface Dr. Getts uniquely melds his business, pathology and immunology understanding to identify value creating strategic and product development opportunities.
Dr. Getts also holds a visiting academic position at Northwestern University and is Deputy Editor of Cellular Immunology. He has over twenty-eight patent / applications and has published his academic work in top tier scientific journals including Nature Biotechnology, the Journal of Experimental Medicine and The Proceedings of The National Academy of Science. In the last 3 years he has obtained in excess of $2 million in grant funding.
Prior to co-founding Cour, Daniel was Director Of Research & Development at Tolera Therapeutics Inc, and was pivotal in moving the lead compound from proof-of-concept into Phase 3. Daniel was a key member of the senior management team leading the company’s R&D efforts and most importantly was instrumental in developing the company’s intellectual property, while supporting the clinical, regulatory & financing programs of the company. In these roles he assisted in raising over $10 million in venture capital and $2 million in non-dilutive capital. Before his time at Tolera, Dr. Getts was Managing Director of his own Life Science Consultancy that assisted in licensing, venture capital diligence support, product & market valuations and medical writing. Dr Getts holds a Masters of Business (MBA), from Western Michigan University (2012), a Ph.D. in Medicine (2008) and a Bachelor of Medical Science (1st Class Honors, 2004) from the University of Sydney.
Jeffrey Rona is a Managing Director at Rona Capital, a Life Sciences focused transaction advisory firm. Jeff has over 20 years of experience in corporate finance, as both an investment banker and as the senior financial officer for development stage life sciences companies. As a senior financial executive, Jeff has raised over $450 million of capital, completed two liquidity events and negotiated several licensing agreements. From 2006-2011, Jeff was Chief Business Officer for GlobeImmune, Inc., and successfully raised approximately $65 million of private capital for the company. In 2009, he completed a broad oncology partnership with Celgene, Inc. that brought $40 million of capital into the Company and included the potential for downstream milestones and royalties of over $500 million. Prior to GlobeImmune, Jeff was the CFO of AlgoRx Pharmaceuticals, where he successfully raised $65 million of private equity and completed the sale of the Company to Corgentech, Inc. Jeff also raised approximately $130 million while with Antigenics, this included a $72 million IPO. As an investment banker, Jeff provided services to clients in a wide range of industries, including Healthcare, General Industrial, Real Estate, Lodging and Gaming. Jeff started his career at Coopers & Lybrand in the Tax Department. He has a B.S. in Accounting from Case Western Reserve University.